A new study increases max-dose guidance for semaglutide. This offers hope for those who didn’t reach their weight goals. The ...

Hims & Hers is under scrutiny for promoting compounded weight-loss drugs in a Super Bowl ad without clear FDA approval or ...

As Ozempic use rises, some patients report unexpected nasal symptoms, prompting researchers to investigate this new and unusual side effect.

Semaglutide, a medication widely used for diabetes and weight loss, may offer another unexpected benefit -- it could help ...

Research reveals semaglutide's effectiveness in decreasing alcohol consumption and cravings, highlighting its potential for treating alcohol use disorder.

A new study suggests that semaglutide, a drug commonly used for diabetes and obesity, may also help reduce alcohol ...

The data, published in JAMA Psychiatry, add to the growing body of evidence supporting the use of GLP-1 receptor agonists for ...

The SELECT trial findings indicated that a dose of 2.4mg of semaglutide could help prevent a decline in renal functions in non-diabetic, obese patients with cardiovascular disease. Patients taking ...

A trial exploring the use of a higher dose of Novo Nordisk's GLP-1 agonist semaglutide has shown that patients with obesity who were taking the drug were able to shed more than a fifth of their ...

“Unlike traditional dosing, which primarily targets appetite suppression and glucose regulation, microdosing semaglutide may provide a more gradual, sustained effect on the brain, immune system ...

New York, New York--(Newsfile Corp. - February 9, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Novo Nordisk (NYSE: NVO) and ...